Infection Risk With Biologic Therapy for Psoriasis: Report From the AAD Meeting

At the 75th Annual Meeting of the American Academy of Dermatology, Dr. Jashin J. Wu spoke about the risk for infection in patients treated with biologics for psoriasis. Dr. Wu reviews data on TNF inhibitors compared to nonbiologic therapy, as well as secukinumab, ixekizumab, and guselkumab trial results. The risk for candidal infections is discussed for the IL-17 inhibitors.